ANL
ANL clinical trials: Adlai Nortye Group Ltd.
Every trial on ClinicalTrials.gov where Adlai Nortye Group Ltd. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 10
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ANL on the catalyst calendar · ANL registry changes
- Primary completion Dec 31, 2028Sponsor estimatePhase 1NCT07686445A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 ExpressionAdlai Nortye Biopharma Co., Ltd. · Solid Tumor (Phase I)RecruitingANLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 1NCT07639047An Initial Evaluation of AN8025 in Solid TumorsAdlai Nortye Biopharma Co., Ltd. · Advanced Solid Tumor (Phase 1)RecruitingANLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2028Sponsor estimatePhase 1NCT07252479Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS MutationsAdlai Nortye Biopharma Co., Ltd. · Solid Tumors (Phase 1)RecruitingANLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 1NCT04999384First in Human, Dose Escalation Study of AN4005Adlai Nortye Biopharma Co., Ltd. · Advanced Solid TumorRecruitingANLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2, 2025ActualPhase 3NCT04338399The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCCAdlai Nortye Biopharma Co., Ltd. · Head and Neck CancerCompletedANLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 24, 2025ActualPhase 1NCT04975958Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid TumorsAdlai Nortye Biopharma Co., Ltd. · Locally Advanced Solid TumorCompletedANLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimatePhase 1NCT05191667AN0025 and Chemoradiotherapy Combination in Esophageal CancerAdlai Nortye Biopharma Co., Ltd. · Esophageal CancerSuspendedANLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2024ActualPhase 1NCT04432857AN0025 and Pembrolizumab Combination in Advanced Solid TumorsAdlai Nortye Biopharma Co., Ltd. · Triple-negative Breast CancerUnknown statusANLLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2022ActualPhase 1NCT05519059Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast CancerAdlai Nortye Biopharma Co., Ltd. · Advanced or Metastatic Breast CancerCompletedANLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2021ActualPhase 1NCT03152370Preoperative Radiotherapy and E7046 in Rectum CancerAdlai Nortye Biopharma Co., Ltd. · Neoadjuvant Therapy in Rectal CancerCompletedANLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2027Sponsor estimatePhase 1NCT05358691A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC ParticipantsRutgers, The State University of New Jersey · Lung Cancer Stage IIIWithdrawnANLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner